2. Academic Validation
  3. Design, synthesis, and pharmacology of a highly subtype-selective GluR1/2 agonist, (RS)-2-amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid (Cl-HIBO)

Design, synthesis, and pharmacology of a highly subtype-selective GluR1/2 agonist, (RS)-2-amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid (Cl-HIBO)

  • J Med Chem. 2003 May 22;46(11):2246-9. doi: 10.1021/jm020588f.
Esben J Bjerrum 1,  Anders S Kristensen,  Darryl S Pickering,  Jeremy R Greenwood,  Birgitte Nielsen,  Tommy Liljefors,  Arne Schousboe,  Hans Bräuner-Osborne,  Ulf Madsen
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, The Danish University of Pharmaceutical Sciences, 2 Universitetsparken, DK-2100 Copenhagen, Denmark.
PMID: 12747796 DOI: 10.1021/jm020588f
Abstract

On the basis of structural studies, chloro-homoibotenic acid (Cl-HIBO) was designed and synthesized. Cl-HIBO was characterized in binding and electrophysiology experiments on native and cloned subtypes of GluRs. Electrophysiological selectivities ranged from 275 to 1600 for GluR1/2 over GluR3/4. The potent AMPA receptor activity was strongly desensitizing and the neurotoxicity similar to AMPA. Thus, Cl-HIBO is the most subtype selective agonist reported to date on GluR1/2, and offers a new standard for selectively studying subtypes of AMPA receptors.

Figures
Products